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Abbreviations 23	
HPV, human papillomavirus; BPV, bovine papillomavirus; VLP, virus-like particle; 24	
Ab, antibody; Ag, antigen; PsV, pseudovirion; HSPGs, heparin sulfate proteoglycans; 25	
cryoEM, electron cryomicroscopy; Fab, antigen-binding fragment; SEAP, secreted 26	
alkaline phosphatase; cLIA, competitive Luminex immunoassay. 27	
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Summary 31	
Persistent high-risk human papillomavirus (HPV) infection is linked to cervical 32	
cancer. Two prophylactic virus-like particle (VLP)-based vaccines have been 33	
marketed globally. Here, we review the approaches employed to generate HPV 34	
pseudovirions (PsV) that mimic native virions and to assess the neutralization activity 35	
of HPV antibodies in patient sera. The PsV-based neutralization assay was developed 36	
to study the virology of HPV and to evaluate vaccine efficacy. Specifically, this 37	
system has been used to evaluate the efficacy of neutralization antibodies in sera 38	
elicited by vaccination or natural infection or to assess the functional characteristics of 39	
monoclonal antibodies. We also review the antibody binding modes observed in 40	
virus-antibody complexes from the work done on virions, PsVs or VLPs. The 41	
neutralizing epitopes are localized on surface loops of the L1 capsid protein, at 42	
various locations on the capsomere. Different neutralization antibodies exert their 43	
neutralizing function via different mechanisms. Some antibodies neutralize the virion 44	
by inducing conformational changes in the viral capsid, which can result in 45	
concealing the binding site for a cellular receptor like 1A1D-2 against dengue virus, 46	
or inducing premature genome release like E18 against EV71 [1, 2]. 47	
Higher-resolution details on the epitope composition of HPV neutralizing antibodies 48	
would shed light on the structural basis of the highly efficacious vaccines and aid the 49	
design of next generation vaccines. For the current vaccines, certain assays can be 50	
developed on the basis of epitope information for improved quality analysis and for 51	
monitoring the manufacturing process to ensure product consistency. This is critical in 52	
Yorgo Modis  11/10/2015 12:04 PM
Deleted:	neutralizing 53	
Yorgo Modis  11/10/2015 12:04 PM
Deleted:	exert their neutralization functions54	
Yorgo Modis  11/10/2015 12:07 PM
Deleted:	the epitopes recognized by 55	
Yorgo Modis  11/10/2015 12:07 PM
Deleted:	 56	
Yorgo Modis  11/10/2015 12:07 PM
Deleted:	the 57	
Yorgo Modis  11/10/2015 12:06 PM
Deleted:	 as 58	
Administrator  11/3/2015 9:51 AM
Deleted:	Some neutralizing antibodies induce 59	
conformational changes in the viral capsid, 60	
suggesting that the virus may recognize 61	
multiple cellular receptors during cell entry.62	
Yorgo Modis  11/10/2015 12:09 PM
Deleted:	better63	
4	
	
the comparability exercise for process improvement or process scale up to meet 64	
market demand. For next generation vaccine design, better understanding of the 65	
structural basis of the type-specific functional epitopes could aid the design of 66	
antigens with cross-type protection activity through epitope redesign or recombination 67	
such as loop grafting in hybrid VLPs [3-5]. 68	
	69	
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Introduction 71	
  Human papillomavirus (HPV) is recognized as the causative agent of cervical 72	
cancer and virtually all cervical cancers are related to the presence of oncogenic HPV 73	
DNAs [6-8]. In addition, genital warts are also caused by non-oncogenic HPV types 74	
although they are regarded as benign. HPVs are small non-enveloped DNA viruses 75	
that belong to the Papovaviridae family. Two late viral proteins, the major L1 and the 76	
minor L2, form the viral capsid [9, 10]. The L1 protein can spontaneously 77	
self-assemble into virus-like particles (VLPs) [11]. Currently, two globally licensed 78	
VLP-based vaccines, Gardasil® and Cervarix® (initially introduced in 2006) have 79	
been proven to effectively prevent HPV infection and to reduce HPV-related 80	
morbidity [12-17]. The two vaccines can induce a strong immune response and elicit 81	
functional L1-specific antibodies. The conferred protective immunity is primarily due 82	
to the viral neutralization function of the antibodies that may bind the incoming 83	
authentic virions[18-21]. As reported in the literature, all the identified antibodies 84	
against L2 such as RG1, 14H6, K4L2 andK18L2 were raised using the recombinant 85	
L2 protein. The neutralizing activities of these antibodies were demonstrated with the 86	
PsV-based neutralization system.[22-24] Because viral neutralization appears to 87	
involve both L1 and L2, the pseudotyped virus (PsV) neutralization model was 88	
developed to study the virology of HPV and evaluate the vaccine potential of the 89	
VLPs. The PsV-based neutralization assay was utilized to evaluate the efficacy of 90	
neutralization antibodies in sera elicited by vaccination or natural infection. Different 91	
PsV systems encapsidating the SEAP or RFP as the reporter have been used to 92	
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evaluate the neutralization titers in the serum obtained from VLP-vaccinated women, 106	
or women naturally infected with HPV, or prenatal pregnant women [25-27]. PsV was 107	
generated by transfecting the L1 and L2 genes into the 239FT cells. PsVs 108	
encapsidating the reporter gene were harvested by lysing the cells. Subsequently, the 109	
antibodies with a serial dilution was mixed with the titered PsV and then the mixture 110	
was added into the 239TT cells. Antibody-mediated PsV neutralization is evaluated 111	
by detecting the reporter activity such as SEAP activity [28]. Neutralizing antibodies 112	
play a key role in preventing viral infection via different mechanisms [29]. The 113	
neutralization mechanisms were reflected in the different binding sites located on the 114	
major capsid protein L1 or the minor capsid protein L2. If the high-resolution 115	
structures of Ab-Ag complexes were determined, a better understanding of the 116	
neutralization mechanism of different mAbs would be achieved. However, this 117	
information is rather limited at this stage. Such knowledge of the details of 118	
identification and characterization of binding sites for neutralization antibodies would 119	
aid in the design of the next generation of vaccines and in the quality control of 120	
existing vaccines during vaccine manufacturing [30]. 121	
 122	
Mimicking native virions with HPV pseudovirions 123	
The lack of permissive and productive cell cultures for HPV has impeded the study 124	
of virus-neutralizing mechanisms of antibodies, the monitoring of viral infection and 125	
other virological studies [31]. With the need for measuring neutralizing antibodies to 126	
high-risk genital HPVs such as HPV16 and HPV18 in the evaluation of vaccine 127	
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efficacy, pseudovirion expression systems have been developed for the in vitro 128	
generation of HPV pseudovirions and for a quantitative in vitro assay for infectivity 129	
evaluation (Figure 1). 130	
  In early studies, Zhou et al. used recombinant vaccinia virus to produce bovine 131	
papillomavirus type-1 (BPV-1) VLPs containing both L1 and L2 capsid proteins in 132	
vitro. This system served as an in vitro model to identify the BPV-1 cellular receptor 133	
[32]. In a separate study, Semliki Forest virus was chosen by Roden et al. to express 134	
the papillomavirus virion proteins for generating pseudotyped papillomaviruses in 135	
vitro [33]. This system has not only permitted the analysis of the ability of antibody 136	
cross-type neutralization but also provided insight into the mechanism and specificity 137	
of papillomavirus genome packaging and infection.  138	
  Unckell et al. generated HPV33 pseudovirions by the assembly of VLPs in COS-7 139	
cells containing multiple copies of a marker plasmid [34]. In addition, HPV18 140	
pseudovirions were prepared using recombinant vaccinia viral expression vectors that 141	
were transfected into mammalian 293T cells [35]. This type of pseudovirion was 142	
shown to be infectious, as it could transfer β-galactosidase activity or confer 143	
resistance to puromycin to a number of cell types when the pseudovirions 144	
encapsidated plasmids containing either the β-galactosidase gene or the 145	
puromycin-resistance gene, respectively. This finding indicated that intracellular 146	
episomal DNAs of suitable sizes can be encapsidated by the HPV18 L1 and L2 147	
proteins without the need for any HPV packaging signal, facilitating the infection of 148	
other cells. This finding facilitated the development and refinement of subsequent 149	
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pseudovirion neutralization systems. Kawana et al. developed a cell-free system for 151	
generating infectious HPV16 pseudovirions [36]. The HPV16 capsid proteins L1 and 152	
L2 were expressed and co-assembled into VLPs in insect cells (Sf9). The HPV16 153	
VLPs were then disassembled in the presence of the reducing agent, 154	
2-mercaptoethanol and reassembled by removal of the reducing agent in the presence 155	
of a β-galactosidase expression plasmid. The in vitro construction of this pseudovirion 156	
system with marker plasmids would be potentially useful in developing an assay for 157	
evaluating virus-neutralizing antibodies from animal or human sera. Coursaget and 158	
colleagues also used the similar disassembly/assembly method on VLPs isolated from 159	
insect cells (Sf21) [37, 38]. The marker genes were then encapsidated in the process 160	
of disassembly/assembly. Another study by Zhao et al. suggested that the packaging 161	
of the genome within papillomavirus pseudovirions also involves the interaction of 162	
the L2 protein with specific DNA sequences and these authors also demonstrated that 163	
the PsV capsid has the potential to encapsidate plasmids up to 10.2 kb in size [39]. 164	
Rossi et al. utilized Saccharomyces cerevisiae to generate HPV16 pseudovirions 165	
[40]. In addition to the plasmid encoding the HPV16 capsid proteins, another target 166	
plasmid containing the green fluorescent protein gene was used to monitor the 167	
delivery of the plasmid into mammalian cells upon infection. The reporter gene 168	
expression could be analyzed by fluorescence activated cell sorting in vitro and 169	
detected by confocal microscopy in vivo. Thus HPV16 pseudovirions produced in 170	
yeast may be useful for both in vitro transduction and in vivo gene delivery. Buck et 171	
al. chose secreted alkaline phosphatase (SEAP) as the reporter molecule with signal 172	
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amplification in the presence of an appropriate enzymatic substrate [41]. The SEAP 175	
reporter plasmid which contains the SV40 origin of replication and codon-modified 176	
papillomavirus capsid genes, L1 and L2, were co-transfected into a 293 cell line, 177	
293TT, that was engineered to express high levels of SV40 large tumor antigen (LT) 178	
to produce high-titer pseudovirions. The LT antigen unwinds DNA containing the 179	
SV40 origin of replication and initiates reporter plasmid replication. High titers (at 180	
least 106 pseudovirions from a 75 cm2 flask of cells) can be routinely achieved due to 181	
the presence of SV40 origin of replication. The PsV encapsidating the SEAP reporter 182	
plasmid was used to develop a high-throughput in vitro neutralization assay with a 96 183	
well plate format. Through this method, antibody-mediated PsV neutralization is 184	
detected by a reduction in SEAP activity. The SEAP activity was monitored using a 185	
highly sensitive chemiluminescent reporter system. This PsV-based neutralization 186	
assay was amenable for routine assays of large numbers of clinical samples with 187	
desired high throughput and high sensitivity due to enzyme turnover and 188	
chemiluninescence detection [26]. 189	
To further improve sensitivity, Bousarghin et al. developed a new method of HPV 190	
VLP-DNA complex formation to generate HPV16 and HPV31 pseudovirions [42]. 191	
This method was also sensitive for detecting the very low amount of neutralization 192	
antibodies after natural infection. It was also suitable for testing neutralization 193	
antibodies from human sera after vaccination. 194	
  Because the mechanism of a successful L1-based vaccine presumably relies on the 195	
in vitro generation of functional antibodies, the development and improvement of 196	
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PsV-based neutralization assays has enabled the implementation of this assay in 209	
evaluation of neutralization antibodies after both immunization and natural infection. 210	
 211	
Assessment of the neutralization activity of HPV antibodies 212	
Prophylactic vaccines confer protection mainly through the elicitation of 213	
neutralizing antibodies. Therefore, the evaluation of neutralizing antibody levels is 214	
highly desirable for predicting vaccine efficacy. The development of in vitro HPV 215	
PsV-based neutralization assays has gradually met the need for the functional 216	
evaluation of human or animal serum samples post-vaccination. The PsV-based 217	
neutralization assay has been highly effective for quantifying potentially protective 218	
antibody responses against HPV acquired through natural infection and in 219	
prophylactic vaccine studies. 220	
Yeager et al. demonstrated that HPV pseudovirions with β-lactamase as a reporter 221	
constitute a novel and efficient approach to detect and characterize HPV neutralizing 222	
antibodies. The results showed that no significant differences were observed between 223	
the HPV11 athymic mouse neutralization assay and the HPV11 PsV-based 224	
neutralization assay using a panel of sera samples with a range of titers differing by 225	
more than 300-fold. This also indicated that the PsV-based assay could detect the 226	
majority of functional antibodies elicited with the VLP immunization. The PsV-based 227	
neutralization assays were predominantly type specific for the tested serum. 228	
Significant cross-reactivity could only be observed between the closely types at the 229	
lowest serum dilution (1:100) such as HPV6 and HPV11 [27]. Pastrana et al. 230	
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developed a sensitive high-throughput neutralization assay that was based on 234	
pseudovirions encapsidating a SEAP reporter gene [26]. This neutralization assay has 235	
been validated for HPV16 and HPV18 by analyzing the neutralization titers in serum 236	
samples of VLP-vaccinated women and women naturally infected with HPV. The 237	
results demonstrated that SEAP-based HPV neutralization assays directly measured 238	
the activity of antibodies relevant to vaccine efficacy and natural infection studies. 239	
Additionally, the HPV16 PsV-based neutralization assay is more sensitive than 240	
ELISA method when assessing antibodies in sera from unvaccinated women. The 241	
greater sensitivity was demonstrated by testing the neutralization activity of the sera 242	
from the individuals who were HPV16 DNA positive but HPV16 ELISA negative. 243	
Krajden et al. prepared the HPV16 and HPV18 PsVs using red fluorescent protein as 244	
a reporter [25]. They utilized this system to analyze the prevalence of HPV16 and 245	
HPV18 neutralization antibody levels in sera from prenatal pregnant women. 246	
Furthermore, HPV16 and HPV18 type-specific neutralizing antibodies from natural 247	
infection can be reliably measured and quantitated by the PsV-based neutralization 248	
assay. In addition, with the specificity of neutralizing antibody detection, the assay 249	
could be used in epidemiological investigation for the prior exposure population to 250	
vaccine types in order to optimize the use of the vaccine and monitor the antibody 251	
response induced by the vaccine. 252	
The PsV-based neutralization assay is more reliable than the VLP-based ELISA as 253	
a measure of neutralizing antibodies. The PsV-based assay usually measures the 254	
functional neutralizing antibodies that are thought to be relevant to immune protection 255	
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induced by vaccination. 266	
To improve the type coverage and amenability for automation, Sehr et al. 267	
developed a high-throughput and automated neutralization assay with improved 268	
sensitivity for HPV16, 18, 31, 45, 52, 58 and BPV1 [43]. To fulfill a high throughput 269	
of the assay, the assay plate preparation was separated from the readout of the 270	
neutralization assay. Large batches of 384-well assay plates with serially diluted 271	
serum samples were prepared by an automated liquid handling system. This improved 272	
the throughput of the assay, making it more amenable for further automation. In 273	
addition, authors utilized the luciferase as the reporter. Compared to the SEAP, the 274	
use of the luciferase increased the sensitivity of the assay with higher signal to 275	
background ratios. The analytic sensitivity has been demonstrated for analyzing the 276	
World Health Organization international antibody standards in sera for HPV16 and 277	
HPV18. Accordingly, increased robustness and decreased assay variation was 278	
demonstrated, in addition to its improved sensitivity. 279	
The correlation between the PsV-based neutralization assay and other serological 280	
assays used to evaluate the neutralizing antibodies was also investigated. Brown et al.  281	
assessed the correlations between the PsV-based neutralization assay and the 282	
competitive Luminex immunoassay and immunoglobulin G Luminex immunoassay 283	
[44]. In this assessment, subsets of serum samples were selected from three prior 284	
clinical trials of the quadrivalent HPV vaccine. The results showed that the three 285	
assays gave results that were highly concordant and reflected measurement of 286	
neutralization antibodies (or functional titer). Robbins et al. also compared the SEAP 287	
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neutralization assay with both the competitive Luminex immunoassay (cLIA) and the 298	
VLP-coating based ELISA [45]. The data demonstrated a good correlation among 299	
these assays. Krajden et al. made another assessment of the HPV16 and HPV18 300	
antibody response by the pseudovirion neutralization assay, Merck competitive 301	
Luminex (Merck cLIA) and Merck total IgG Luminex (Merck TIgG) immunoassays 302	
in a reduced dosage quadrivalent HPV vaccine trial [46]. The correlation between the 303	
PsV-based neutralization assay and cLIA was better for HPV18 than for HPV16, 304	
whereas the correlation between the PsV-based neutralization assay and total IgG was 305	
similar for both of the viral types. This assessment indicated that the PsV-based 306	
neutralization assay was more sensitive than cLIA and likely more specific than the 307	
total IgG immunoassay. 308	
Although good correlation among different assays has been demonstrated, the cLIA, 309	
SEAP-NA, ELISA are biologically and technically different assays [45, 47]. They 310	
measure the antibody response of serum in different aspects. The cLIA assay 311	
developed by Merck was mainly used in the clinical trials to measure all the 312	
neutralizing antibodies of all IgG classes in serum samples that compete for binding 313	
to a specific epitope on VLP surface, e.g. V5 for HPV16, J4 for HPV18 with an 314	
indication of a binding fluorescent signal strength. This assay is highly type specific. 315	
Therefore, in a single assay the individual reactivity to multiple VLPs can be 316	
simultaneously detected owing to the multiplexing capacity of the Luminex platform. 317	
However, the major disadvantage is that it measures only the neutralizing antibodies 318	
that bind the specific epitope, which make up a subset of the total antibodies elicited. 319	
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Thus, this assay may underevaluate the potentially protective antibody response 327	
induced by the vaccine, which are non-overlapping with the tracing antibody. 328	
SEAP-NA reflects the overall serum neutralizing antibodies by measuring a 329	
reporter gene product. This assay is considerably more laborious but recently it has 330	
been developed to be highly throughput and highly sensitive. Therefore, this assay is 331	
used primarily to correlate with the clinical protection potential of the serum samples. 332	
The ELISA developed by GSK measures the antibodies that bind to a VLP antigen 333	
fixed on a solid face. Conformational heterogeneity of the surface immobilized 334	
antigen is an inevitable issue for plate based ELISAs. The signal was detected by 335	
adding a secondary antibody conjugated with an enzyme e.g. alkaline phosphatase. It 336	
has the disadvantage of potentially detecting the nonneutralizing antibodies elicited by 337	
the VLPs. 338	
The PsV-based neutralization assay is still the gold standard among various assays 339	
for evaluating the potentially protective antibodies. The implementation of the 340	
PsV-based neutralization assay is of the utmost importance in the evaluation of 341	
clinical serum samples to demonstrate the efficacy of prophylactic HPV vaccines. 342	
Comparison and correlation could be better determined by the first antibody standard 343	
established by WHO Expert Committee on Biological Standardization [48]. 344	
 345	
Different binding sites for neutralizing antibodies to the HPV capsid 346	
Natural infection with HPV or vaccination with HPV L1 VLP-based vaccines can 347	
induce a complex antibody response. A wide array of different antibodies directed to 348	
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different epitopes presented on the VLP surface can be elicited by the virions or 354	
VLP-based immunogens. The neutralizing antibodies usually exert their function by 355	
blocking the binding and entry of HPVs into host cells. HPV16 binding to heparin 356	
sulfate proteoglycans (HSPGs) on the basement membrane was firstly reported by 357	
Johnson et al. using a murine cervicovaginal challenge model in vivo. Additionally, 358	
initial HPV16 binding occurs via heparin sulfate proteoglycans (HSPGs) located 359	
either on the epithelial cell surface or on the basement membrane was also verified in 360	
vitro by Knappe et al. and Richards et al [49-51]. HSPGs were first described as HPV 361	
binding receptors using HPV11 L1 VLP on HaCaT cells [52, 53]. The other studies 362	
showed that HSPGs were essential for infection using HPV16 PsV and HPV33 PsV 363	
on COS-7 cells [49, 54]. The exterior surface of HPVs is mainly composed of the L1 364	
capsid protein with 5 surface loops. HPV16 L1 residues Lys278 and Lys361 on the 365	
top of the pentamer were identified as the primary attachment sites to HSPGs, which 366	
demonstrated a direct interaction between HPV16 L1 and HSPGs [50]. Thus, the 367	
interaction between neutralizing antibodies and the major capsid protein can block the 368	
virions from binding to the target host cells, thus inhibiting the subsequent cell entry 369	
process. 370	
  Various neutralizing mAbs have been isolated by different labs to further elucidate 371	
the neutralization mechanism and the specific binding sites of neutralizing mAbs. 372	
Three different binding modes for neutralization antibodies on the viral capsid have 373	
been determined to date (Figure 2). Bovine papillomavirus and human papillomavirus 374	
are in the same genus and are highly similar to each other, particularly in regards to 375	
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their capsid surface structure [55]. Therefore, BPV has commonly been used as a 382	
surrogate to study the biological profile of HPV. Two immunocomplexes of the BPV1 383	
major capsid protein L1 and two neutralizing mAbs were analyzed by electron 384	
cryomicroscopy (cryoEM) and three-dimensional image reconstruction to 13 Å 385	
resolution [56]. mAb #9 is representative of a set of neutralization antibodies that can 386	
inhibit viral binding to the host cell surface. In the cryoEM structure, mAb #9 bound 387	
to the major L1 molecules of both pentavalent and hexavalent capsomeres. The 388	
epitope of mAb #9 was located in the outer tips of capsomeres (Figure 2). The other 389	
neutralizing antibody, mAb 5B6, can efficiently neutralize the papillomaviruses 390	
without significantly inhibiting viral binding to the host cell surface. Thus, this type of 391	
neutralizing antibody may neutralize the virus by preventing capsid uncoating and 392	
thus blocking the release of viral DNA into the nucleus. Structural analysis showed 393	
that mAb 5B6 did not bind to pentavalent capsomeres, which reflected the significant 394	
structural and environmental difference of its epitope between the pentavalent and 395	
hexavalent capsomeres [56]. A similar observation was made for the different 396	
conformations of pentavalent versus hexavalent capsomeres. The epitope localization 397	
showed that mAb 5B6 bound both monovalently and bivalently to the sides of 398	
hexavalent capsomeres approximately two-thirds of the way down from the outer tips 399	
(Figure 2). Other work on recombinant vaccine VLPs by Zhao et al. demonstrated 400	
two different binding models for two different neutralizing antibodies (H11.B2 for 401	
HPV11 and H16.V5 for HPV16) using cryoEM image reconstruction [57, 58]. Both 402	
H16.V5 and H11.B2 showed highly efficient neutralization activity in the 403	
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pseudovirion neutralization assay. These antibodies also recognized immuno 404	
dominant epitopes when analyzed by competition assay using human sera from 405	
naturally infected individuals. The cryoEM structure of the VLP-Fab complex in 406	
comparison to VLP alone revealed that the binding site of mAb H11.B2 was located 407	
at the center of the capsomere, coincident with the L2 binding sites in the capsid, 408	
indicating 72 potential binding sites per capsid [57]. However, the other well-studied 409	
mAb H16.V5 with an extremely high neutralization efficiency showed a different 410	
binding mode on the apex of the capsomere [57, 59]. H16.V5 bound only to 411	
capsomeres with six neighboring capsomeres (at the 3-fold axes of symmetry), but 412	
there was no evidence from the density map for its binding to the pentavalent 413	
capsomeres (at 5-fold axes of the symmetry) (Figure 3). Based on the cryoEM 414	
structures, there are 300 potential binding sites for mAb H16.V5 due to steric 415	
hindrance or different structures between hexavalent versus pentavalent capsomeres 416	
in the recombinant icosahedral VLPs. 417	
A recent study by Lee et al. also determined the spatial structure of the 418	
immunocomplex of H16.V5 and HPV16 pseudovirions [59]. The complete epitope of 419	
H16.V5 was identified using cryoEM and 3D image reconstruction. Based on the 420	
experimental methods using the model of VLP-Fab complexes, the H16.V5 epitope 421	
was found to be composed of the antigenic loops BC, DE and EF, in addition to the 422	
previously identified epitopes located in the FG loop and HI loop. The study indicated 423	
that the binding of H16.V5 Fab induced a global conformational change. The study 424	
showed that the H16.V5 Fab bound to the hexavalent capsomeres as well as to the 425	
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pentavalent capsomeres. H16.V5 Fab also bound preferentially to the hexavalent 429	
capsomeres over the pentavalent capsomeres (Figure 3). This preferred binding 430	
suggested that the affinity for the two binding sites was different and that this 431	
phenomenon might exist intrinsically or be induced by H16.V5 Fab binding. In 432	
addition, structural consolidation in the base of the capsomere as well as on the 433	
surface flexible loop was observed by the binding of H16.V5 to the capsid (Figure 3). 434	
The other recent study by Guan et al. showed that Fab fragment from three 435	
additional HPV16-specific antibodies, mAbs H16.1A H16.14J and H263.A2, had 436	
complex and overlapping epitopes similar to the H16.V5 epitope [61]. CryoEM image 437	
reconstructions showed that the DE loop formed the core of each mAb footprint, and 438	
that the mAbs also bound to the FG, HI, DE and EF loops, although the participation 439	
of the latter loops varied between the antibodies (Figure 3). 440	
  In addition to the roles played by major capsid protein L1, the minor capsid protein 441	
L2 was also determined to be involved in the viral cell entry process, a critical step for 442	
viral infection. A subtle conformational change is triggered by the interaction between 443	
HSPGs and the HPV capsid that further leads to the exposure of an amino-terminal 444	
portion of L2. Subsequently, the cleavage of L2 by furin is required for further 445	
infection, which results in additional changes to the capsid conformation. More 446	
importantly, during this furin cleavage process, a broadly neutralizing epitope of the 447	
L2 protein is exposed. The exposure of this epitope was first characterized with the 448	
neutralizing mAb RG-1 [22, 62]. 449	
The observation of different binding modes for various neutralization antibodies 450	
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against the major capsid protein L1 or the minor capsid protein L2 at a higher 451	
resolution would shed light on the mechanisms of how HPV virions could be 452	
neutralized during cell attachment or entry. This will likely soon be achievable with 453	
the improvement of direct electron detectors and image reconstruction software in 454	
cryoEM. 455	
 The encouraging clinical trial results and long-term follow-up results have validated 456	
the efficacy of the launched vaccines (Cervarix®, Gardasil® and Gardasil®9). The 457	
protective immunity conferred by vaccination is due to the presence of functional 458	
epitopes in the vaccine antigens. Neutralizing antibody responses are believed to be 459	
the most direct evidence of vaccine efficacy and the primary mechanism of 460	
vaccine-induced protective immunity [63]. Therefore, integrity of the correct spatial 461	
conformation and sufficient exposure of the functional epitopes are essential during 462	
the bioprocessing of vaccine antigens. Some epitope-based assays were designed and 463	
developed to evaluate antibody response in clinical sera to verify vaccine 464	
immunogenicity. Secreted alkaline phosphatase neutralization assay has been used to 465	
quantify the neutralizing antibody response elicited by Cervarix® and Gardasil® [12, 466	
26, 64-67].More recently, serological assays for an E.coli-derived VLP-based vaccine 467	
were performed with a slightly different format of PsV-based assay [68-70]. For 468	
Gardasil®, the competitive Luminex immunoassay was developed to measure 469	
neutralizing antibodies with high-sensitivity by competing for binding to one epitope, 470	
e.g., H16.V5 for HPV16 and H18.R5 for HPV18. [71-74]. With a better 471	
understanding of the functional epitopes, more epitope-based assays will be 472	
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reasonably designed [75]. Therefore, the accurate epitope determination at molecular 474	
level will shed light on assay developments to monitor the manufacturing process of 475	
vaccines and to evaluate the effective antibody response in clinical sera. 476	
Discussion 477	
Currently, there are two prophylactic HPV vaccines on the market, the bivalent 478	
vaccine containing the VLP antigen for HPV16/18 (Cervarix® from GSK) and the 479	
quadrivalent (or recently-licensed nonavalent) vaccine against HPV6, 11, 16, and 18 480	
(with 31, 33, 45, 52, 58) from Merck. Both vaccines are based on VLPs as the active 481	
component, produced by expressing the L1 protein using recombinant technology. 482	
The expressed L1 proteins self-assemble into VLPs that resemble the native virions 483	
with specific spatial structural features. This high degree of resemblance of the VLPs 484	
to viral capsids is the structural basis for their ability to elicit neutralization and 485	
functional antibodies for prevention of viral infection. Two issues are the questions 486	
being discussed when licensing a new biosimilar HPV vaccine: a) what is the minimal 487	
level of neutralizing antibody required for protection? b) what endpoint(s) should be 488	
used for evaluation of a new HPV vaccine – clinical (i.e., CIN2+), persistent infection 489	
or virological endpoint? The former question is difficult to address due to the high 490	
efficacy of the vaccines. For the latter questions, consensus has been reached 491	
gradually among scientists that persistent infection is the pre-requisite for CIN1, CIN2 492	
and higher precancerous lesions, thus, using endpoints other than the initially used 493	
“CNI2+” for Gardasil and Cervarix is feasible. Based on what has been learned since 494	
the initial licensure of Gardasil in 2006, a trove of data has been accumulated in the 495	
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understanding of the vaccine efficacy and endpoints that can be used for the 497	
evaluation of HPV vaccines: persistent infection (>6 Mo) or virological endpoints 498	
(such as virus neutralization activity of serum samples using the PsV-based 499	
neutralization assay). This has been reflected in the WHO guidelines for licensing 500	
existing or new HPV vaccines in their countries/regions by the respective national 501	
regulatory agencies [Recommendations to assure the quality, safety and efficacy of 502	
recombinant human papillomavirus virus-like particle vaccines. WHO Expert 503	
Committee On Biological Standardization 2015: 504	
http://www.who.int/biologicals/BS2252_HPV_Recommendations_30062015_tz.pdf?505	
ua=30062011.]. 506	
The presence of functional neutralizing antibodies is the basis for conferring 507	
protection against HPV infection. Neutralizing antibodies played a key role in 508	
preventing HPV infection by blocking attachment to cells or inhibiting the cell entry 509	
process depending on the specific epitopes on the viral capsid they recognize. The 510	
major capsid protein, L1, harbors most of the neutralizing epitopes. This is also the 511	
basis for the function of the currently licensed L1-based vaccines. However, some 512	
reports showed some neutralizing Abs could be elicited by recombinant L2 protein. 513	
Since L2 has higher degree of amino acid sequence homology as compared to L1, it is 514	
also a target for broad spectrum vaccine development. Since most PsV systems 515	
contain both L1 and L2, therefore the same PsV-based neutralization assay can be 516	
used to assess the function of the Abs elicited by either L1- or L2-based vaccines.   517	
In addition, the PsV neutralization assay could provide an alternative method in 518	
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bioprocessing for VLP quality analysis for assuring the presence of neutralization 600	
epitopes on antigens. This analysis can be carried out with in vivo mouse potency 601	
assays. Mouse potency was used to evaluate the immunogenicity of vaccines with the 602	
indication of the ED50 value. Specifically, mice were immunized with serially diluted 603	
vaccine and the serum samples were collected four weeks after immunization. 604	
Subsequently, the anti-vaccine antigen antibodies were detected in an antigen-coating 605	
ELISA assay. The ED50 value was calculated with indication of the {something 606	
missing here} that would result in 50% seroconversion for the tested animals [82]. 607	
The titer of neutralization antibodies reflected of the level of functional Abs elicited 608	
by immunization with immunogens harboring  conformational and functional 609	
epitopes. For many infectious diseases, assays to detect neutralizing antibodies are 610	
used to assess the immunogenicity of prophylactic vaccines. In vitro PsV-based 611	
neutralization assays involve measuring the inhibition of HPV pseudovirion binding 612	
and infection of cultured cells by employing a reporter gene to score the level of 613	
infection. 614	
Due to the type-specificity of the current L1 VLP-based vaccines, a broad-spectrum 615	
next generation HPV vaccine needs to be developed that would prevent the infection 616	
of more additional HPV types for broader type coverage. A nonavalent vaccine, with 617	
L1 antigens of HPV6, 11, 16, 18, 31, 33, 45, 52, and 58, was recently licensed in the 618	
USA (Gardasil®9 developed by Merck) [83-85]. The HPV capsid contains the major 619	
L1 protein and the minor L2 protein. The L1 protein is abundantly present on the viral 620	
surface, which harbors the immunodominant epitopes inducing strong B cell 621	
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responses. However, the L2 protein is barely visible to the immune system. Only 629	
when the virus binds to the basement membrane of host cell does L2 become exposed 630	
due to conformational changes in the capsid[50, 86]. Its neutralization epitopes are 631	
deemed to be transiently exposed after furin cleavage in the viral infection process. 632	
The process was induced by the interaction between L1 and HSPGs that triggers a 633	
conformational change of the capsid. It is the transient exposure that induces the 634	
immune response to generate the specific antibodies. Several cross-neutralizing 635	
antibodies have been identified and studied extensively, such as RG1 recognizing 636	
residues 17-36 of L2 and the other two antibodies K4L2 and K18L2 targeting the sites 637	
located at residues 20-38 of L2, which are exposed after furin 638	
cleavage.[22-24].Therefore, the L2 protein is also a candidate for a broad-spectrum 639	
HPV prophylactic vaccine with the conserved epitopes located at the N-terminus of 640	
the L2 protein. Recently, efforts have been made to develop an L2-based prophylactic 641	
vaccine for the development of the next generation of HPV vaccine, which has had 642	
some success [87-91]. 643	
Understanding of the clinically relevant epitopes is critical for vaccine design and 644	
quality control in the manufacturing process of vaccines. The mAbs recognizing 645	
immuno dominant epitopes are useful molecular tools. The binding activity to the 646	
neutralizing mAbs can serve as a surrogate marker for VLP antigens. Therefore, 647	
mAbs can be utilized for process monitoring and product assessment to ensure the 648	
product consistency for VLP-based vaccines. More specifically, the entire 649	
conformational epitope recognized by the mAb HPV16.V5 was recently identified by 650	
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Lee et al., and this work also advanced the understanding of the neutralization 663	
mechanism of the well-studied HPV16.V5 [59]. This mAb was also used in the 664	
clinical serology assay for Gardasil® in the competitive Luminex-based immunoassay, 665	
where the effectiveness of competition of the serum samples with H16.V5 was used 666	
as a surrogate marker for vaccine efficacy against HPV16 [45, 60, 71-73]. The 667	
binding of HPV16.V5 to the capsid resulted in a significant conformational change 668	
and structural consolidation that altered the capsid-Ab complex. This binding ordered 669	
the apical loops of HPV16 and consolidated the “invading-arm” structure. In addition, 670	
this conformational change was transmitted to the lower region of the capsomere and 671	
tightened the intercapsomeric connection at the capsid floor.  672	
A similar phenomenon of conformational changes induced by mAb binding was 673	
also observed in other viral capsid-Ab complexes. The neutralizing mAb 1A1D-2 674	
strongly neutralized dengue virus types 1, 2, and 3. The binding of this mAb to the 675	
envelope glycoprotein E of dengue virus altered the arrangement of the surface 676	
glycoproteins. The Fab molecules might capture the transient viral intermediate 677	
conformation, further hiding the 1A1D-2 epitopes exposed for Fab binding. This 678	
change is likely the potential mechanism by which this neutralization antibody could 679	
inhibit viral attachment to host cells [1]. Another example is the binding of 680	
neutralization mAb E18 to the mature human enterovirus 71 (EV71), which induces 681	
the conformational change in the capsid. mAb E18 recognized the conformation of 682	
empty and immature particles of EV71, which are similar to the “A” particles when 683	
the EV71 recognizes a potential host cell before genome release. The binding of E18 684	
25	
	
to mature virions induced a conformational change that transformed the infectious 685	
virions into “A” particles. This mechanism demonstrated that mAb E18 could 686	
neutralize the virus by inducing genome release. Therefore, such a characteristic made 687	
the E18 a potential therapeutic Ab candidate [2]. 688	
  In summary, the PsV-based neutralization system has been broadly used in the 689	
efficacy evaluation of neutralization antibodies generated by vaccination or natural 690	
infection. Antibodies could exert their viral neutralizing functions via different 691	
mechanisms. These include blocking the binding between viruses and cell receptors 692	
and altering the epitopes recognized by the cell receptors by inducing conformational 693	
changes in the viral capsid. Three binding modes for HPV capsid and mAb were 694	
determined using cryoEM image reconstruction techniques at intermediate resolution. 695	
Higher resolution structural determination will aid in the understanding of the epitope 696	
details and the functional mechanism of neutralization mAbs. In addition, better 697	
knowledge regarding the mAb neutralization mechanism will advance process 698	
understanding and process control during bioprocessing in vaccine production and in 699	
the design and development of the next generation vaccines [30]. 700	
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Figure Legends 972	
Fig. 1 The different forms, natural virion, pseudovirion, and VLP of papillomavirus 973	
and their applications. (A) Surface representation of the BPV cryoEM image 974	
reconstruction. The native virions were used in biological studies on viral assembly 975	
and cell entry, among others. (Adapted from [56]) (B) CryoEM image reconstructions 976	
of HPV16 pseudovirions that were used to develop the PsV-based neutralization assay. 977	
(Adapted from [92]) (C) CryoEM image reconstructions of HPV16 VLPs. Two 978	
VLP-based prophylactic vaccines have been globally approved for clinical use. 979	
(Adapted from [57]) Native virion and pseudovirion are composed of the major L1 980	
and the minor L2 proteins. They also both encapsidate DNA. However, VLPs do not 981	
contain the L2 protein, which is self-assembled from L1 protein only without DNA 982	
involvement. The structures of all three forms have been determined and they all 983	
showed icosahedral symmetry. Although the native virion and pseudovirion contain 984	
the L2 protein, the precise structure of L2 is poorly resolved in all the available 985	
structures. 986	
 987	
Fig. 2 Three binding modes for neutralizing antibodies against papillomavirus capsid. 988	
(Left) mAb H11.B2 binding to HPV11 VLP (the DE loops on L1) indicates that the 989	
binding sites are located at the center of the capsomere. (Middle) mAb 5B6 binding to 990	
the two L1 molecules of the adjacent hexavalent capsomeres. (Right) mAb #9 binding 991	
to the outer surface of the hexavalent capsomere. mAb H16.V5 binding to HPV16 992	
VLP (FG and HI loops on L1) shows that H16.V5 only preferentially binds to the 993	
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outer surface of the hexavalent capsomeres. The inset pictures were used to further 1010	
clarify the interaction models between antibody and antigen. 1011	
 1012	
Fig. 3 HPV16.V5 binding sites and specific amino acid residues involved at the 1013	
Ab-Ag interface. (A) The footprint of antibodies H16.V5, H16.1A H16.14J and 1014	
H263.A2 mapped to the stereographic projection of a capsomer. The virus surface 1015	
was represented as a quilt format for the icosahedral symmetric unit, with the polar 1016	
angles φ and θ representing the latitude and longitude. The color bar indicates the 1017	
different antigenic L1 loops and each mAb epitope was denoted using dashed circle. 1018	
The common epitope indicated by arrow includes all residues identified in each mAb 1019	
footprint. (Adapted from [61]) (B) A 3D reconstruction structure based on cryo-EM 1020	
data of mAb H16.V5 binding to HPV16 VLP (FG and HI loops on L1) shows that 1021	
H16.V5 only binds to the hexavalent capsomeres but not the pentavalent capsomeres. 1022	
(EMDB:28370). (Adapted from [57]) (C) The 3D structural model of mAb H16.V5 1023	
binding to HPV16 VLP, with magenta for H16.V5 binding site on FG loop and red on 1024	
HI loop, and cyan for VLP. (Adapted from [30]) (D) The HPV16.V5 Fab binds 17 1025	
residues across five loops from two neighboring L1 proteins. The contacting residues 1026	
are shown as spheres with the residue names and loops labeled. Within the five loops, 1027	
three loops, BC, DE, FG, are contributed by the first L1 protein. The other two loops, 1028	
DE and HI are contributed by the second neighboring L1 protein. (Adapted from [59]) 1029	
(E) The accurate epitope location of HPV16.V5 on the exterior flexible loops with a 1030	
total of identified 16 amino acid residues. The loops with red represent the major 1031	
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contribution from one L1 molecule. The blue HI loop confers the minor interaction by 1040	
a second neighboring L1. 1041	



